Venture Capital News Daily
   Your Source for Venture Capital and Private Equity Financings
   Massinvestor/VC News Daily      
   Venture Capital News Daily on RSS Venture Capital News Daily on Facebook Venture Capital News Daily on Twitter
VC DATABASE   /   MOBILE APP  /  CELEBRITY VCs   /   VENTURE TRACKR   /   ARCHIVE   /   ABOUT US
VC-funded Company:


OncoMyx Therapeutics
Phoenix BioScience Center
445 N. Fifth Street
Phoenix, AZ 85004
https://www.oncomyx.com/

OncoMyx Therapeutics, a startup launched from Arizona State University (ASU), develops oncolytic immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response and treat cancer. Successful immuno-oncology (IO) cancer treatment generally requires combination therapy, and oncolytic viruses (OVs) have emerged as a safe and effective IO complement. The company's MYXV platform, spun out from ASU, is poised to be a best-in-class OV approach, and the top OV team has assembled around MYXV to create important new therapeutic options for cancer patients.

Key Contact
NameTitleE-Mail
Steve PottsCEOsp@oncomyx.com


Funding Events
DateAmountTypeInvestors
06/05/19$25,000,000Series A Boehringer Ingelheim Venture Fund  
City Hill Ventures
Delos Capital  
Korea Investment Partners
Madison Partners
Xeraya Capital  
 
Massinvestor/VC News Daily
617-620-4606


© 2018 Massinvestor, Inc.